BHP01 / Chengdu Brilliant Pharma - LARVOL DELTA

Phase I Clinical Study of ?-PD-L1/DLL3 CAR-T in Patients With R/R SCLC (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Sichuan University | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Sichuan University | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase I Clinical Study of Α-PD-L1/DLL3 CAR-T in Patients with R/R SCLC (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Sichuan University | Initiation date: Jun 2024 ➔ Jan 2025 | Trial primary completion date: Jul 2025 ➔ Jun 2026

CAR T-Cell Therapy • Trial initiation date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Sichuan University

CAR T-Cell Therapy • New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor